JP2022035920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022035920A5 JP2022035920A5 JP2020187268A JP2020187268A JP2022035920A5 JP 2022035920 A5 JP2022035920 A5 JP 2022035920A5 JP 2020187268 A JP2020187268 A JP 2020187268A JP 2020187268 A JP2020187268 A JP 2020187268A JP 2022035920 A5 JP2022035920 A5 JP 2022035920A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- combination
- patient
- protein
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067388P | 2020-08-19 | 2020-08-19 | |
| US63/067,388 | 2020-08-19 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022035920A JP2022035920A (ja) | 2022-03-04 |
| JP2022035920A5 true JP2022035920A5 (enExample) | 2023-11-17 |
| JP7657041B2 JP7657041B2 (ja) | 2025-04-04 |
Family
ID=77666491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020187268A Active JP7657041B2 (ja) | 2020-08-19 | 2020-11-10 | 併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220073888A1 (enExample) |
| EP (1) | EP4199955A1 (enExample) |
| JP (1) | JP7657041B2 (enExample) |
| KR (1) | KR20220022828A (enExample) |
| CN (1) | CN116096874A (enExample) |
| AU (1) | AU2020267165B2 (enExample) |
| CA (1) | CA3098818A1 (enExample) |
| TW (1) | TW202207937A (enExample) |
| WO (1) | WO2022038191A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024089196A1 (en) | 2022-10-28 | 2024-05-02 | Astrazeneca Ab | Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg |
| KR20260113060A (ko) * | 2023-11-16 | 2026-07-21 | 하이로리스 디벨롭먼츠 에스에이 | 피부경유 관상동맥 중재술 (pci)을 겪은 환자에서 허혈성 사건의 치료, 감소 또는 예방에 사용을 위한 티카그렐러 iv |
| WO2025104274A1 (en) * | 2023-11-16 | 2025-05-22 | Hyloris Developments Sa | Ticagrelor iv for use in the prevention of thromboembolic events |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7247300B1 (en) | 2002-11-07 | 2007-07-24 | Apt Therapeutics, Inc. | Therapeutic use of soluble CD39L3 |
| EP2133430B1 (en) | 2004-02-27 | 2014-12-17 | APT Therapeutics, Inc. | Design and therapeutic use of adpase enhanced apyrases |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| BR112012017243A2 (pt) | 2010-01-13 | 2017-09-19 | Apt Therapeutics Inc | constructos terapêuticos de apirase, agentes de apirase, e métodos de produção |
| WO2011088231A1 (en) * | 2010-01-13 | 2011-07-21 | Apt Therapeutics, Inc. | Apyrase therapy for bleeding conditions |
| RS66536B1 (sr) | 2016-04-21 | 2025-03-31 | Astrazeneca Ab | Tablete za oralno raspadanje |
-
2020
- 2020-11-10 AU AU2020267165A patent/AU2020267165B2/en active Active
- 2020-11-10 CA CA3098818A patent/CA3098818A1/en active Pending
- 2020-11-10 JP JP2020187268A patent/JP7657041B2/ja active Active
- 2020-11-11 KR KR1020200150157A patent/KR20220022828A/ko active Pending
- 2020-11-11 TW TW109139411A patent/TW202207937A/zh unknown
-
2021
- 2021-08-18 WO PCT/EP2021/072954 patent/WO2022038191A1/en not_active Ceased
- 2021-08-18 US US17/405,670 patent/US20220073888A1/en not_active Abandoned
- 2021-08-18 EP EP21766429.1A patent/EP4199955A1/en active Pending
- 2021-08-18 CN CN202180056616.9A patent/CN116096874A/zh active Pending
-
2023
- 2023-07-14 US US18/352,414 patent/US12668785B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016074740A5 (enExample) | ||
| RU2010101892A (ru) | Гиалуронидаза и способ ее применения | |
| EP3528828B1 (en) | Terlipressin composition for use in treating ascites | |
| JP2021514354A5 (enExample) | ||
| JP2023537921A5 (enExample) | ||
| JP2005506345A5 (enExample) | ||
| JP2023510609A (ja) | Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法 | |
| WO2021037933A1 (en) | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer | |
| JP2019507174A5 (enExample) | ||
| JP2007501806A5 (enExample) | ||
| CA2516458C (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| AU2024246525A1 (en) | Methods and uses for treating nausea and emesis | |
| JP2025509343A5 (enExample) | ||
| AU2011202639A1 (en) | Compositions and methods for treating myelodysplastic syndrome | |
| EP2392329B1 (en) | Compositions for use in treating myelodysplastic syndrome | |
| JP2021169472A5 (enExample) | ||
| JP2023550043A5 (enExample) | ||
| RU2690677C1 (ru) | Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью | |
| Witika et al. | Clinical applications of long acting injectables: Systemic and local drug delivery | |
| JP2022521266A5 (enExample) | ||
| AU2019312904A1 (en) | Combination therapy for treating cancer | |
| JP2023518645A (ja) | Ｇｌｐ－１の投薬レジメン | |
| Peyrin-Biroulet et al. | S2 Impact of Obefazimod Induction Therapy on Histologic and Combined Histologic and Endoscopic Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Week 8 Results from the Phase 2b Induction Trial | |
| JP2023507764A5 (enExample) | ||
| CN117243948A (zh) | 包含瑞香素的组合物在制备风湿性关节炎药物中的应用 |